REBEC

Public trial

Clinical trial with convalescent plasma for Covid-19 therapy

Date of registration: 07/07/2021 ^(mm/dd/yyyy)
Last approval date : 07/07/2021 ^(mm/dd/yyyy)
Last revision: 1

Study type:

Interventional

Comparative study of analgesic efficacy between phosphate codeine in combination with paracetamol and oxycodone hydrochloride, after extractions of impacted lower third molars.

Date of registration: 07/07/2021 ^(mm/dd/yyyy)
Last approval date : 07/07/2021 ^(mm/dd/yyyy)
Last revision: 1

Study type:

Interventional

Evaluation portable devices in diagnosis and follow-up of eye diseases during the COVID-19 pandemic

Date of registration: 07/06/2021 ^(mm/dd/yyyy)
Last approval date : 07/06/2021 ^(mm/dd/yyyy)
Last revision: 1

Study type:

Interventional

Neuromuscular electrical stimulation protocol in intensive care unit-acquired weakness (ICUAW) patients and COIVD19: a clinical, prospective and randomized study

Date of registration: 07/06/2021 ^(mm/dd/yyyy)
Last approval date : 07/06/2021 ^(mm/dd/yyyy)
Last revision: 1

Study type:

Interventional

Responsiveness of central sensitisation outcomes in older people with low back pain

Date of registration: 07/05/2021 ^(mm/dd/yyyy)
Last approval date : 07/05/2021 ^(mm/dd/yyyy)
Last revision: 2

Study type:

Interventional

Responsiveness of clinical outcomes and functional tests in older people with chronic low back pain

Date of registration: 07/05/2021 ^(mm/dd/yyyy)
Last approval date : 07/05/2021 ^(mm/dd/yyyy)
Last revision: 1

Study type:

Interventional

Evaluation of the effect of Brazilian Propolis on mouth Inflammation (Mucositis) in patients undergoing treatment for Head and Neck Cancer

Date of registration: 07/02/2021 ^(mm/dd/yyyy)
Last approval date : 07/02/2021 ^(mm/dd/yyyy)
Last revision: 1

Study type:

Interventional

Manual Hand Osteopathic for headache patients

Date of registration: 07/01/2021 ^(mm/dd/yyyy)
Last approval date : 07/01/2021 ^(mm/dd/yyyy)
Last revision: 1

Study type:

Interventional

Evaluation of the effectiveness and cost-effectiveness of functional foods in glycemic control

Date of registration: 07/01/2021 ^(mm/dd/yyyy)
Last approval date : 07/01/2021 ^(mm/dd/yyyy)
Last revision: 1

Study type:

Interventional

Covidreab study: pulmonary rehabilitation on physical capacity, functional capacity, and quality of life in post-covid-19: randomized, controlled double-blinded clinical trial

Date of registration: 07/01/2021 ^(mm/dd/yyyy)
Last approval date : 07/01/2021 ^(mm/dd/yyyy)
Last revision: 1

Study type:

Interventional

Effect of electrical stimulation on the head for patients with stress after a traumatic event: controlled phase II clinical trial

Date of registration: 07/01/2021 ^(mm/dd/yyyy)
Last approval date : 07/01/2021 ^(mm/dd/yyyy)
Last revision: 1

Study type:

Interventional

Effect of Inhaled Nitric Oxide for the treatment of COVID-19

Date of registration: 09/22/2020 ^(mm/dd/yyyy)
Last approval date : 06/30/2021 ^(mm/dd/yyyy)
Last revision: 2

Study type:

Interventional

Effectiveness of the Fiocruz Vaccine ® against different variants of SARS-COV-2 in Botucatu-SP

Date of registration: 06/30/2021 ^(mm/dd/yyyy)
Last approval date : 06/30/2021 ^(mm/dd/yyyy)
Last revision: 1

Study type:

Observational

Treatment of wrist dorsal ganglion cyst. Randomized clinical trial.

Date of registration: 06/29/2021 ^(mm/dd/yyyy)
Last approval date : 06/29/2021 ^(mm/dd/yyyy)
Last revision: 1

Study type:

Interventional

Efficacy of at-home bleaching with buccal and palatal application of teeth

Date of registration: 06/29/2021 ^(mm/dd/yyyy)
Last approval date : 06/29/2021 ^(mm/dd/yyyy)
Last revision: 1

Study type:

Interventional

Effect of anesthetic ankle block, through local infiltration of medications Dexmedetomidine and Ropivacaine, for postoperative pain relief: a study with random selection of patients

Date of registration: 06/29/2021 ^(mm/dd/yyyy)
Last approval date : 06/29/2021 ^(mm/dd/yyyy)
Last revision: 1

Study type:

Interventional

A study about the effect of a telephone call on the quality of Bowel Preparation

Date of registration: 06/28/2021 ^(mm/dd/yyyy)
Last approval date : 06/28/2021 ^(mm/dd/yyyy)
Last revision: 1

Study type:

Interventional

Effectiveness of intervention to Improve Adherence to Home Care of suspected or confirmed mild cases of Covid-19

Date of registration: 06/28/2021 ^(mm/dd/yyyy)
Last approval date : 06/28/2021 ^(mm/dd/yyyy)
Last revision: 1

Study type:

Interventional

Evaluation of the effectiveness and safety of a health product.

Date of registration: 06/28/2021 ^(mm/dd/yyyy)
Last approval date : 06/28/2021 ^(mm/dd/yyyy)
Last revision: 1

Study type:

Interventional

Comparison between Orientation and Hiking Modalities in healthy aged

Date of registration: 06/25/2021 ^(mm/dd/yyyy)
Last approval date : 06/25/2021 ^(mm/dd/yyyy)
Last revision: 1

Study type:

Interventional

Username/Password

News

03/05/2021

Brazil is the 11th in total of studies on covid-19

Brazil is part of the restricted group of countries that have published the most studies on covid-19 since the beginning of the new coronavirus pandemic. As of October 17, there have been 168,546 scientific publications related to the disease worldwide. Of these, 4,029 are signed by researchers working in the country. The number puts Brazilian production in the 11th position in the world ranking. It is ahead of that produced by countries like Holland, Switzerland and Japan.

The information is contained in a survey carried out by the USP Academic Information Management Agency, at the request of the Dean of Research. It uses the Dimensions platform, an international database with daily updates. According to USP's Dean of Research, Sylvio Canuto, the numbers confirm the trend of good performance in Brazilian scientific production.

"Brazilian science has developed a lot. We are at a very good stage of development. In the last five years, Brazil has been appearing as the 13th country that has published the most scientific articles and research reviews", said Canuto. "This year, over a period of eight months, Brazilian researchers were able to improve their performance in the specific case of covid-19."

https://www.correiobraziliense.com.br/brasil/2020/11/4890627-brasil-e-o-11-em-total-de-estudos-sobre-covid.html

03/04/2021

Brazilian platform accelerates registration for studies on Covid-19

The Oswaldo Cruz Foundation launched on Tuesday, 24, an express approval process in the Brazilian Registry of Clinical Trials (ReBEC) for clinical research on COVID-19. The so-called fast track may reduce the normal approval period, from up to a few weeks, to less than 48 hours. Scientists around the world will have quick access to modeling studies already underway, avoiding rework and favoring cooperation. The objective is to shorten the time between the beginning of the research, the testing and the arrival of medicines, vaccines and other innovations to society. Fast track users will receive online support through four dedicated phone lines, using messages in free apps like Telegram or Whatsapp, or even through the chat provided by the platform. They will also be able to be answered via voice call via wi-fi, with a scheduled time per message, using the same applications. In addition to the 24-hour operating system with automated e-mail messages every day, human service will be expanded, starting earlier, at 8 am, and going until 8 pm. “Our curatorship and technology team accepted the challenge and will work in shifts to meet the demand, which today is spread around the world”, guaranteed Luiza Silva, coordinator of ReBEC and specialist in risk and crisis communication. The existing fast tracks - zika, dengue, yellow fever and malaria - and the attendance to other studies will not be interrupted. The platform has more than 3,800 approved records, all of which have been validated by the most important scientific journals in the world and open to public consultation and is the only primary record in the world in Portuguese recognized by the World Health Organization.

https://www.medicina.ufmg.br/plataforma-brasileira-acelera-registro-para-estudos-sobre-covid-19/

03/04/2021

Brazilian platform accelerates registration for studies on Covid-19

On March 24, the Oswaldo Cruz Foundation launched an express approval process in the Brazilian Registry of Clinical Trials (ReBEC) for clinical research on COVID-19. The so-called fast track may reduce the normal approval period, from up to a few weeks, to less than 48 hours. Scientists around the world will have quick access to modeling studies already underway, avoiding rework and favoring cooperation. The objective is to shorten the time between the beginning of the research, the testing and the arrival of medicines, vaccines and other innovations to society. Fast track users will receive online support through four dedicated phone lines, using messages in free apps like Telegram or Whatsapp, or even through the chat provided by the platform. They will also be able to be answered via voice call via wi-fi, with a scheduled time per message, using the same applications. In addition to the 24-hour operating system with automated e-mail messages every day, human service will be expanded, starting earlier, at 8 am, and going until 8 pm. “Our curatorship and technology team accepted the challenge and will work in shifts to meet the demand, which today is spread around the world”, guaranteed Luiza Silva, coordinator of ReBEC and specialist in risk and crisis communication. The existing fast tracks - zika, dengue, yellow fever and malaria - and the attendance to other studies will not be interrupted. The platform has more than 3,800 approved records, all of which have been validated by the most important scientific journals in the world and open to public consultation and is the only primary record in the world in Portuguese recognized by the World Health Organization.

ICICT/Fiocruz

https://portal.fiocruz.br/noticia/plataforma-brasileira-acelera-registro-para-estudos-sobre-covid-19

03/04/2021

ReBEC: online platform disseminates research and clinical trials conducted in Brazil

All studies that evaluate the clinical, pharmacological or side effects of drugs in humans are called clinical trials. In order to conduct these studies in Brazil, participating institutions must resort to their own Ethics Committees or partner institutions, which analyze research according to the National Ethics and Research Council (Conep) and the National Health Surveillance Agency (Anvisa).

To meet national and regional information needs and provide transparency to studies, the Brazilian Registry of Clinical Trials (ReBEC) - an online platform for experimental and observational studies - disseminates various research on a specific disease or drug that is underway in Brazil, through data that does not always find space in scientific journals. Managed by Fiocruz and publicly owned, the service has free access, free of charge for anyone who wants to register or consult approved records.

Adriana Martins

https://portal.fiocruz.br/noticia/rebec-plataforma-line-divulga-pesquisas-e-ensaios-clinicos-feitos-no-brasil

03/04/2021

BRAZILIAN RESEARCHERS CREATE BUCAL ANTISEPTIC THAT INACTIVES CORONAVIRUS

Scientists from national institutions have announced the creation of a mouthwash formula capable of inactivating 96% of the proliferation of the new coronavirus (Sars-CoV-2) in the upper airways. The formula is based on Phtalox technology, a compound initially created to treat bad breath and improve gum health, revealed the magazine Galileu.

The study was carried out by four public institutions - USP School of Dentistry (FOB) in Bauru (SP), USP Biological Sciences Institute, State University of Londrina (PR) and Federal Institute of Paraná, in partnership with the Research Center and Innovation at DentalClean.

MARCELO DE VALÉCIO

https://www.ictq.com.br/farmacia-clinica/2327-pesquisadores-brasileiros-criam-antisseptico-bucal-que-inativa-coronavirus